The most powerful
GLP-1 available.
For less.
Luma's compounded Tirzepatide contains the same active ingredient as Mounjaro® and Zepbound® — delivering up to 22% body weight reduction in clinical trials.*
More receptors.
More results.
Tirzepatide works on two hormone pathways instead of one — giving it a significant edge over traditional GLP-1 medications like Semaglutide.
- Targets GLP-1 receptor only
- Avg. 15% body weight reduction
- Reduces appetite & slows digestion
- Same ingredient as Ozempic®
- Great starting point for most patients
- Targets both GIP & GLP-1 receptors
- Avg. up to 22% body weight reduction
- Stronger appetite suppression
- Same ingredient as Mounjaro® & Zepbound®
- Superior results in head-to-head trials
How Tirzepatide works.
Tirzepatide is the first medication to activate both the GIP and GLP-1 receptors — two powerful hormonal pathways that work together for superior weight loss.
Dual Receptor Action
Unlike Semaglutide which targets only GLP-1, Tirzepatide activates both GIP and GLP-1 receptors simultaneously — amplifying appetite suppression and metabolic benefits.
Boosts Metabolism
GIP receptor activation improves how your body processes fat and glucose, increasing energy expenditure and helping your metabolism work more efficiently throughout the day.
Crushes Cravings
The combined hormonal effect delivers stronger, more sustained appetite suppression than GLP-1 alone — making it significantly easier to maintain a calorie deficit without feeling deprived.
What to expect.
Tirzepatide is safe and well-tolerated by most patients. Side effects are typically mild and improve as your body adjusts to the medication.
🟡 Common Side Effects
- Nausea (most common, especially early)
- Reduced appetite
- Mild constipation or diarrhea
- Headache during dose adjustment
- Mild fatigue in first few weeks
✅ You're Supported
- Same-day provider visits
- 24/7 care team messaging
- Dose adjusted to your body's response
- FSA & HSA eligible
- Payment plans via Affirm available
Yes — Luma's compounded Tirzepatide contains the same active ingredient as Mounjaro® and Zepbound®. It is prepared by a licensed pharmacy based on your provider's prescription. Not an FDA-approved brand-name drug, but the same dual GIP/GLP-1 molecule at a significantly lower cost.
Tirzepatide activates two hormone receptors — GIP and GLP-1 — while Semaglutide targets GLP-1 only. This dual-action mechanism leads to stronger appetite suppression and greater average weight loss (up to 22% vs. ~15% with Semaglutide) in clinical trials.*
Tirzepatide is a once-weekly subcutaneous injection — a very small needle injected just under the skin, typically in the abdomen or thigh. Most patients describe it as virtually painless. Full instructions are included with every shipment.
Most patients notice significantly reduced appetite within the first 1–2 weeks. Visible weight loss typically begins by weeks 4–8. The most dramatic results occur between months 3–6 as your dose reaches its therapeutic level.
Yes to both. Luma Health treatments are FSA and HSA eligible. We also accept Affirm — split your costs into simple monthly payments with no hidden fees, approved in seconds at checkout.
Ready to experience
next-level results?
Complete a short health assessment and meet with a licensed provider — same day visits available.